~~<i id='70C60DF095'><strike id='70C60DF095'><tt id='70C60DF095'><pre id='70C60DF095'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：leisure time 2025-08-25 07:27:35 - browse：5

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

hotspot

focus

leisure time

CourtesyPfizerThenewvaccinesthatprotectolderadultsagainstrespiratorysyncytialvirus,orRSV,maybelinked

WSS

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Antibiotic resistance nearly killed me, so I'm raising awareness of it

RSV vaccines may be linked to small increased risk of developing GBS

House looks to weaken Medicare negotiation

Akili, maker of video game for ADHD, to be acquired for 34 million

International team creates first chimeric human

hotspot

focus

focus

How to save PrEP access — and even expand it

Scientists successfully use ultrasound imaging to map brain activity

Virginia high school admissions case could be legal follow

Latest bird flu infection made farmworker sicker than earlier cases

Drug repurposing or repositioning? The language matters

Why getting cancer drugs just got harder for rural patients

State Dept. review finds Biden bears some blame for Afghanistan failures

Prosthetic arm enables patients to feel the objects they grip

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Addiction doctors spar with methadone clinics over legislation

hotspot

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Akili, maker of video game for ADHD, to be acquired for 34 million

Do more moles mean more problems? Not so, says new study

Addiction doctors spar with methadone clinics over legislation

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

focus

focus

focus

leisure time